4.36
Precedente Chiudi:
$4.45
Aprire:
$4.46
Volume 24 ore:
336.79K
Relative Volume:
0.77
Capitalizzazione di mercato:
$304.38M
Reddito:
$63.39M
Utile/perdita netta:
$-219.51M
Rapporto P/E:
-1.3784
EPS:
-3.1631
Flusso di cassa netto:
$-231.83M
1 W Prestazione:
-7.23%
1M Prestazione:
-18.20%
6M Prestazione:
-32.61%
1 anno Prestazione:
-46.17%
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Nome
Bicycle Therapeutics Plc Adr
Settore
Industria
Telefono
011441223261503
Indirizzo
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc Adr
|
4.36 | 310.66M | 63.39M | -219.51M | -231.83M | -3.1631 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Hold |
| 2025-10-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | Iniziato | Stephens | Equal-Weight |
| 2024-09-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-07 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Iniziato | Cowen | Outperform |
| 2022-07-28 | Iniziato | Barclays | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-04-13 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | SVB Leerink | Outperform |
| 2021-12-09 | Iniziato | Needham | Buy |
| 2021-09-30 | Iniziato | B. Riley Securities | Buy |
| 2021-04-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Iniziato | Oppenheimer | Outperform |
| 2020-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-09-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-06-17 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-17 | Iniziato | Goldman | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
| 2019-06-17 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Bicycle Therapeutics Plc Adr Borsa (BCYC) Ultime notizie
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - Stock Titan
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer - Defense World
Bicycle Therapeutics stock price target lowered to $7 by RBC Capital - Investing.com South Africa
Citizens cuts Bicycle Therapeutics stock price target on strategic shift By Investing.com - Investing.com South Africa
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Truist cuts Bicycle Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift By Investing.com - Investing.com India
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6%Time to Sell? - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase By Investing.com - Investing.com South Africa
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - ChartMill
Comparing Golden Heaven Group (NASDAQ:GDHG) and AiRWA (NASDAQ:YYAI) - Defense World
Bicycle Therapeutics Plc Adr Azioni (BCYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):